US5773457A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions
Assignee: Individual
•
Filing: 1995-05-18
•
Granted: 1998-06-30
•
Expires: 2015-05-18
Abstract
Abstract The present invention involves the novel use of various classes of drugs, such as H 2 and H 3 agonists, as erectogenic agents in the treatment of male and female sexual dysfunction.
Inventors
- 👤 Cesar Roberto Dias Nahoum
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 22:04
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/50; A61K31/13; A61K31/155; A61K31/41; A61K31/415; A61K31/4164; A61K31/417; A61K31/4178; A61K31/425; A61K31/427; A61K31/435; A61K31/44; A61K31/4427; A61K31/4439; A61K31/47; A61K31/485; A61K33/00; A61K33/24; A61K33/26; A61K45/00; A61K45/06
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
26 words
A method of treating sexual dysfunction in a mammal in need thereof which comprises administering to said mammal an effective amount of an H 3 agonist.
Claim 2
Independent Claim
26 words
A method of treating sexual dysfunction in a mammal in need thereof which comprises administering to said mammal an effective amount of an H 3 agonist.
Claim 3
Dependent Claim
80 words
The method according to claim 1 wherein the H 3 agonist is of the formula ##STR15## wherein R 1 , R 2 , R 3 and R 4 are each hydrogen or methyl, or R 1 and R 2 taken together represent a methylene, and R 3 is hydrogen, a methyl or a carboxy with the proviso that R 1 , R 2 , R 3 and R 4 are not simultaneously methyl groups, or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
17 words
The method according to claim 2 wherein the compound is R-α-methylhistamine or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
66 words
The method according to claim 1 wherein the H 3 agonist is further administered in combination with one or more therapeutically active which are an H 2 agonist, histamine, an α-adrenergic blocker, a dopamine D 2 -antagonist, nitric oxide releaser, cyclooxgenase inhibitors, H 1 antagonists, prostaglandin or an analog thereof having a vasoactive function, calcium antagonists, CGRP, VIP, phentolamine, physiostigmine, neostigmine, hydralazine, sodium nitroprusside, or phenoxybenzamine.
Claim 6
Dependent Claim
26 words
The method according to claim 1 which further comprises administering the H 3 agonist with a second therapeutic agent which either facilitates, potentiates or is erectogenic.
Claim 7
Dependent Claim
55 words
The method according to claim 5 wherein the the second therapeutic agent is an H 2 agonist, histamine, an α-adrenergic blocker, a dopamine D 2 -antagonist, nitric oxide releaser, prostaglandin or an analog thereof having a vasoactive function, calcium antagonists, CGRP, VIP, phentolamine, cyclooxgenase inhibitors, H 1 antagonists, physiostigmine, neostigmine, hydralazine, sodium nitroprusside, or phenoxybenzamine.
Claim 8
Dependent Claim
24 words
The method according to claim 5 wherein the second therapeutic agent is an H 2 agonist, sulpiride, papaverine, PGE 1 , phentolamine, or histamine.
Claim 9
Dependent Claim
16 words
The method according to claim 1 wherein the composition is administered intracavernous, topically, transdermally, or intraurethrally.
Claim 10
Dependent Claim
19 words
The method according to claim 4 which further comprises administering with the H 3 agonist a penetration enhancing agent.
Claim 11
Dependent Claim
36 words
Unit dose packaging of a single use i.c. injection wherein said unit dose packaging contains an effective amount of from about 1500 mcg to about 15,000 mcg of an H 3 receptor agonist that promotes erection.
Claim 12
Dependent Claim
36 words
Unit dose packaging of a single use i.c. injection wherein said unit dose packaging contains an effective amount of from about 1500 mcg to about 15,000 mcg of an H 3 receptor agonist that promotes erection.
Claim 13
Dependent Claim
36 words
Unit dose packaging of a single use i.c. injection wherein said unit dose packaging contains an effective amount of from about 4500 mcg to about 9,000 mcg of an H 3 receptor agonist that promotes erection.
Claim 14
Dependent Claim
36 words
Unit dose packaging of a single use i.c. injection wherein said unit dose packaging contains an effective amount of from about 4500 mcg to about 9,000 mcg of an H 3 receptor agonist that promotes erection.
Claim 15
Dependent Claim
13 words
The method according to claim 1 wherein the mammal is a human being.
Claim 16
Dependent Claim
16 words
The method according to claim 1 which method is applied to animals in the veterinary sciences.
Claim 17
Dependent Claim
21 words
An intracavernousal composition which composition comprises an effective amount of an H 3 agonist and a pharmaceutically acceptable carrier or diluent.
Claim 18
Dependent Claim
21 words
An intracavernousal composition which composition comprises an effective amount of an H 3 agonist and a pharmaceutically acceptable carrier or diluent.
Claim 19
Dependent Claim
21 words
An intraurethral composition, which composition comprises an effective amount of an H 3 agonist and a pharmaceutically acceptable carrier or diluent.
Claim 20
Dependent Claim
21 words
An intraurethral composition, which composition comprises an effective amount of an H 3 agonist and a pharmaceutically acceptable carrier or diluent.
References Cited (Backward Citations)
US3636225A
Cited
US4472376A
Cited
US4311707A
Cited
US4532135A
Cited
US4521421A
Cited
US4801487A
Cited
US4840952A
Cited
US4863911A
Cited
EP0266968A2
Cited
US4801587A
Cited
US5256652A
Cited
EP0346297A1
Cited
US5147855A
Cited
EP0357581B1
Cited
EP0432199B1
Cited
US4931445A
Cited
US5214030A
Cited
US5059603A
Cited
US5145852A
Cited
US5336678A
Cited
US5242391A
Cited
US5474535A
Cited
EP0459377A2
Cited
US5270323A
Cited
US5190967A
Cited
US5192806A
Cited
US5177070A
Cited
US5565466A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-06-29 | 2001-12-29 | 2002-06-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-06-29 | 2005-12-29 | 2006-06-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-06-29 | 2009-12-29 | 2010-06-30 | $7700.00 | Window Closed / Lapsed |